PTC THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
PTC THERAPEUTICS INC. - More news...
PTC THERAPEUTICS INC. - More news...
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
- PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
- PTC Therapeutics Provides Key Regulatory Updates
- PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
- CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
- PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
- PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
- PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
- PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
- PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
- CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
- PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
- PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
- PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
- PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize